Drug Profile
Research programme: RNAi therapeutics - Alnylam/Ionis
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals; Isis Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Ionis Pharmaceuticals
- Class Antisense oligonucleotides; Small interfering RNA
- Mechanism of Action 5 aminolevulinate synthetase inhibitors; Antithrombin III inhibitors; Apolipoprotein A inhibitors; Factor XI inhibitors; Haemostasis stimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute intermittent porphyria; Atherosclerosis; Haemophilia; Hyperlipoproteinaemia; Venous thromboembolism
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Acute-intermittent-porphyria in USA (Parenteral)
- 28 Feb 2019 No recent reports of development identified for research development in Atherosclerosis in USA
- 28 Feb 2019 No recent reports of development identified for research development in Haemophilia in USA (Parenteral)